Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A317 in Previously Treated PD-L1 Positive Urothelial Bladder Cancer
CTR20170071Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by BeiGene. Started Apr 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20170071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170071.